Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Life Threatening Disease Equipment Supplied In Europe
4 equipment items found
Manufactured by:CerTest Biotec S.L. based inSan Mateo de Gállego Zaragoza, SPAIN
CerTest S. pneumoniae one step card test is a coloured chromatographic immunoassay for the qualitative detection of Streptococcus pneumoniae in human urine samples. CerTest S. pneumoniae card test offers a highly sensitive and simple screening assay to make a presumptive diagnosis of pneumoniae caused by Streptococcus pneumoniae in infected ...
Manufactured by:RespInnovation SAS based inSeillans, FRANCE
The newest advancement in Bronchial Clearance therapy – the RespIn Pad. Unique and exceptionally easy to use, the RespIn Pad delivers 'focused pulsations' to the patient in super comfortable and highly effective manner – literally pick your programme, lean back against the Pad in a high backed chair or in an inclined bed or wheelchair, press the ON button and your patients can get the ...
Manufactured by:Avelas Biosciences based inLa Jolla, CALIFORNIA (USA)
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat surgeries and improve patient outcomes. Pegloprastide is the only fluorescence-based clinical cancer detection product that uses the ratio of two ...
by:Pure Biologics SA based inWroclaw, POLAND
Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, considerable social and institutional support exists for developing new therapies for such rare diseases. The PB002 ...